Author's posts
Esperion’s Cholesterol Combo Pill Cuts Bad Cholesterol 35%
“Sometimes I think, gosh, it would be great if folks in the investment community could have that opportunity to sit in front of regulators and hear what they have to say,” says Tim Mayleben, Esperion’s chief executive.
Pfizer Drug Reduces Death Rate In Patients With Hearts Damaged By Protein Clumps
An experimental Pfizer drug extended the lives of patients who had a disease in which clumps of protein break apart into toxic substances that damage the heart.
Pfizer Drug Reduces Death Rate In Patients With Hearts Damaged By Protein Clumps
An experimental Pfizer drug extended the lives of patients who had a disease in which clumps of protein break apart into toxic substances that damage the heart.
The Agonizingly Slow Progress Against The Cancer That Killed Aretha Franklin
Our slow progress against pancreatic cancer is representative of the war on cancer writ large. Focus in on pancreatic cancer, and you see that there has been progress for patients with some subtypes for the disease. There are real reasons for hope that…
A Harvard Scientist Thinks He Has A Gene Test For Heart Attack Risk. He Wants To Give It Away Free
“I think in a few years I think everybody will know this number similar to the way we know our cholesterol right now,” muses Sekar Kathiresan, director of the Center for Genomic Medicine at Massachusetts General Hospital and a professor at Harvard Medi…
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
This morning, after 16 years and $2.5 billion in investment, the Cambridge, Mass.-based company Alnylam finally turned a 1998 biology breakthrough into a medicine: a drug called Onpattro to treat the destruction of nerves that results from a rare disea…
RegenXBio Gene Therapy Shows Early Promise Eye Disease; Cholesterol Treatment Results Mixed
A gene therapy being developed by RegenX Bio of Rockville, MD, showed early promise against wet macular degeneration, a leading cause of blindness.
Ovid Therapeutics Drug, Invented 41 Years Ago, May Help People With A Rare Disorder
This morning, Ovid Therapeutics, a small biotechnology company, is announcing data indicating that a drug, gaboxadol, may be of some help for patients with a condition called Angelman Syndrome.
Ovid Therapeutics Drug, Invented 41 Years Ago, May Help People With A Rare Disorder
This morning, Ovid Therapeutics, a small biotechnology company, is announcing data indicating that a drug, gaboxadol, may be of some help for patients with a condition called Angelman Syndrome.
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Regeneron Pharmaceuticals, one of the largest biotechnology companies, and gene therapy upstart Bluebird Bio will team up to invent genetically modified white blood cells that can attack cancer.
